Observational studyScientific reports2025
Association between endogenous lactate accumulation and dysregulated activation of the NLRP3 inflammasome pathway in schizophrenia.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The NLRP3 inflammasome: pathophysiology and therapeutic implications for schizophrenia and neuropsychiatric disorders.Molecular psychiatry · 2026Review
- Metabolic Plasticity in Schizophrenia: Clinical Rehabilitation Meets LC-MS Metabolomics and Neurofeedback.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In this study, we retrospectively analyzed whether serum lactate levels were elevated in patients with schizophrenia (SCZ) and explored cognitive deficits, abnormalities in lactate metabolism, and neuroinflammation in an dizocilpine (MK-801)-induced N-methyl-d-aspartate (NMDA) receptor (NMDAR) inhibition model using the Morris water maze (MWM) test, biochemical assays, immunofluorescence (IF), Western blot (WB), and enzyme-linked immunosorbent assay (ELISA). We found that serum lactate levels were significantly higher than the normal range in patients with schizophrenia, and they were significantly and positively correlated with both length of hospitalization and serum triglyceride levels. In addition, we found that MK-801 induced cognitive deficits in Sprague-Dawley (SD) rats, accompanied by markedly elevated levels of lactate, pyruvate, glutamate and lactate dehydrogenase (LDH) activity in serum and frontal cortex (FCX). MK-801 caused a significant increase in the expression of NOD-, LRR-, and pyrin-containing protein 3 (NLRP3) and Caspase-1 proteins in FCX of rats; and elevated the levels of interleukin (IL)-1β and IL-18 in serum and FCX (P<0.05). We also found that serum lactate was significantly and positively correlated with serum pyruvate and glutamate levels, LDH activity, and IL-1β and IL-18 levels in SD rats. These data suggest that serum lactate is abnormally elevated in both SCZ patients and NMDA receptor inhibition models. Furthermore, there may be a link between MK-801-induced cognitive impairment, elevated serum lactate, and aberrant activation of the NLRP3/Caspase-1/IL-1βinflammatory pathway in rats. Modulation of serum/brain lactate levels and the NLRP3/Caspase-1/IL-1β pathway in SCZ patients may serve as potential targets for improving cognitive impairment in SCZ. Clinical trial registration number: ChiCTR2400091186.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.